prof. dr. F. (Femke) van Wijk

prof. dr. F. (Femke) van Wijk

Full Professor
prof. dr. F. (Femke) van Wijk
  • Laboratory for Translational Immunology (LTI)



Dr. van Wijk obtained her PhD on mechanisms of oral tolerance and allergic sensitization to peanut at the Utrecht University in 2006. After her first postdoctoral training in human immunology in the lab of Prof. B. Prakken at the UMCU she obtained a KNAW fellowship for a 2-year postdoc in the lab of Prof. H. Cheroutre in the La Jolla Institute for Immunology in La Jolla (USA) to work on tissue T cell adaptation . After being awarded a VENI personal fellowship, she moved to the UMCU to start her own research group. For her research on how antigen presenting cells sabotage T cell regulation in local inflammation van Wijk was awarded a prestigious ZonMw VIDI career development grant (2014), and in 2021 she received a ZonMw VICI grant for her work on naïve T cell imprinting and immune development. Her research program aims to elucidate tissue T cell responses in health and inflammation and to translate these insights into tools for (pre-clinical) disease monitoring and therapeutic targeting in chronic inflammatory diseases.  She takes a disease- and age-overarching approach to decipher common and specific pathogenic processes underlying different inflammatory conditions and one of her specific interests is early imprinting of disease. Diseases her group is working on include atopic dermatitis, inflammatory bowel disease, juvenile idiopathic arthritis, juvenile dermatomyositis and immune toxicity following immune therapy in cancer.

 Dr. van Wijk is the author of 85 publications in leading peer-reviewed journals and has extensive experience with national and international scientific advisory committees (NWO off-road program, samenwerkende gezondheidsfondsen PPS Immunology consortia, Sanofi type 2 innovation grant, EU Horizon 2020 REA-FET-OPEN and COFUND). She is participating in several international networks including T_CELL_CONNECT_EUROPE, Eureka Institute for Translational Medicine, and Understanding Childhood Arthritis Worldwide Network that are aimed at (international) exchanges and training of young scientists, knowledge sharing, and enhancing reproducibility of human data. In 2017 Dr. van Wijk received the PhD supervisor of the year award by the Utrecht University Graduate School of Life Sciences.

Dr. van Wijk is a member of the Utrecht Life Sciences (ULS) Program Board for the domain One Health, and scientific director FOCIS (federation of clinical immunology societies) center of excellence.

Side Activities

Scientific director FOCIS (federation of clinical immunology societies) center of excellence UMC Utrecht.

Member Utrecht Life Sciences Program Board, domain One Health

Member scientific advisory committee "Samenwerkende Gezondheidsfondsen PPS Immunologie Consortia"

Fellowship and Awards

ZonMw VICI (2021)

PhD Supervisor (co-promotor) of the year 2017, Graduate School of Life Sciences

Stimulerings Associate Professorship UMCU (2015)

ZonMw VIDI (2014)

ZonMw Veni (2010)

KNAW fellowship Ter Meulen Fund (2007)



Research Output (82)

Human Tregs at the materno-fetal interface show site-specific adaptation reminiscent of tumor Tregs

Wienke Judith, Brouwers Laura, van der Burg Leone M, Mokry Michal, Scholman Rianne C, Nikkels Peter G J, van Rijn Bas B, van Wijk Femke 18 aug 2020, In: JCI Insight. 5 , p. 1-21

Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis

Wienke Judith, Pachman Lauren M, Morgan Gabrielle A, Yeo Joo Guan, Amoruso Maria C, Hans Victoria, Kamphuis Sylvia S M, Hoppenreijs Esther P A H, Armbrust Wineke, van den Berg J Merlijn, Hissink Muller Petra C E, Gelderman Kyra A, Arkachaisri Thaschawee, van Wijk Femke, van Royen-Kerkhof Annet 26 feb 2020, In: Arthritis & Rheumatology. 72 , p. 1214-1226 13 p.

Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients:First clinical and biomarker results from the BioDay registry

Ariëns Lieneke F M, van der Schaft Jorien, Bakker Daphne S, Balak Deepak, Romeijn Margreet L E, Kouwenhoven Tessa, Kamsteeg Marijke, Giovannone Barbara, Drylewicz Julia, van Amerongen Cynthia Catalina Aurora, Delemarre Evelien M, Knol Edward F, van Wijk Femke, Nierkens Stefan, Thijs Judith L, Schuttelaar Marie L A, de Bruin-Weller Marjolein S 1 jan 2020, In: Allergy. 75 , p. 116-126 11 p.

Colonic mucosal kinase activity, cytokine and chemokine profiles in inflammatory bowel disease

Brand E., Roosenboom B., Fernandez B. Malvar, Lutter L., van Koolwijk E., van Lochem E. G., Horje C. S. Horjus Talabur, Reedquist K. A., van Wijk F., Oldenburg B. jan 2020, In: Journal of Crohn's & Colitis. 14 , p. S139-S140

IgA coating of intestinal microbiota is associated with inflammatory bowel disease in twin pairs discordant for inflammatory bowel disease

Brand E., Laenen Y., van Wijk F., de Zoete M., Oldenburg B. jan 2020, In: Journal of Crohn's & Colitis. 14 , p. S010-S011

Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers

Bakker Daphne S, Nierkens Stefan, Knol Edward F, Giovannone Barbara, Delemarre Eveline M, van der Schaft Jorien, van Wijk Femke, de Bruin-Weller Marjolein S, Drylewicz Julia, Thijs Judith L 2020, In: The Journal of Allergy and Clinical Immunology. 147 , p. 189-198 10 p.

Endotyping of adult and paediatric atopic dermatitis; is it one disease?

Thijs J., Bakker D., Delemarre E., de Graaf M., Knol E., Drylewicz J., van Wijk F., Nierkens S., de Bruin-Weller M. sep 2019, In: Journal of Investigative Dermatology. 139 , p. S285-S285

The identification of CCL18 as biomarker of disease activity in localized scleroderma

Mertens J. S., de Jong E. M.G.J., van den Hoogen L. L., Wienke J., Thurlings R. M., Seyger M. M.B., Hoppenreijs E. P.A.H., Wijngaarde C. A., van Vlijmen-Willems I. M.J.J., van den Bogaard E., Giovannone B., van Wijk F., van Royen-Kerkhof A., Marut W., Radstake T. R.D. 1 jul 2019, In: Journal of Autoimmunity. 101 , p. 86-93 8 p.

Dupilumab:Eerste resultaten vanuit het BioDay-register

Ariëns Lieneke F.M., van der Schaft J., Bakker D. S., Balak D. M.W., Giovannone B., Romeijn M., Kouwenhoven T., Kamsteeg M., Drylewicz J., van Wijk F., Nierkens Stefan, Thijs J. L., Schuttelaar M. L., de Bruin-Weller M. S. 1 apr 2019, In: Nederlands Tijdschrift voor Dermatologie en Venereologie. 29 , p. 29-34 6 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet